Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoracic radiotherapy added to durvalumab plus chemotherapy for extensive-stage small-cell lung cancer
NL-OMON60832Phase 3Active, not recruiting
- Sponsor
- Norwegian University of Science and Technology
- Start
- May 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab in small cell lung cancer (SCLC) (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: 1-year overall survival. Started May 2023; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON60832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60832.